Skip to main content
How We Can Help

You’ve got this.
We’ll make sure of it.

Starting a therapy like EXONDYS 51 can be a hopeful but complex time in your family’s life. We’re committed to ensuring that you know what to expect and have assistance at every step of the process. That’s why we developed SareptAssist™, our comprehensive patient support program, designed to provide you with information to help you navigate starting and staying on EXONDYS 51.

Getting started with SareptAssist.

With your consent and signature, your doctor completes and sends in the SareptAssist START form. This form authorizes your Case Manager to start a benefits investigation on your current insurance coverage. Download the form to get the ball rolling.

SareptAssist is a resource available only to those who have been prescribed EXONDYS 51 (eteplirsen). SareptAssist is only available in the U.S.

Logo for SareptAssist, the patient support program for EXONDYS 51 patients
Logo for SareptAssist, the patient support program for EXONDYS 51 patients

Questions? Just give us a call at 1-888-SAREPTA (888-727-3782). Case Managers are available Monday – Friday 8:30am – 6:30pm ET.

Here's how SareptAssist can help:

Get support from a case manager.

One-on-one support from a dedicated Case Manager.

Once you enroll with SareptAssist, you’ll be connected to a dedicated Case Manager with experience in rare diseases, including knowledge of insurance plans and healthcare networks. While your doctor is your primary resource for discussing your medical needs, your Case Manager can be one of your key contacts for questions regarding insurance benefits, coordination of drug delivery, and access.

Insurance benefits

Help navigating your insurance benefits.

Your Case Manager will help you understand how your insurance benefits work and can assist with the appeals process if your initial claim is denied. They can also provide information on options for financial assistance that you may qualify for.

Treatment locations

Assistance with treatment locations.

You may receive EXONDYS 51 infusions at your doctor’s office, an infusion center, or at home. Your Case Manager will help by providing information on locations; discuss these options with your doctor to decide what’s best for your family.

Coordinating delivery

Coordinating delivery of EXONDYS 51.

Once your insurance benefits are confirmed, SareptAssist will work with the providing specialty or hospital pharmacy to coordinate treatment access and drug delivery to your treatment location. 

Support for the long run

Support for the long run.

You can count on SareptAssist support throughout your treatment journey. Whether you are changing insurance companies, appealing a denial of coverage, or planning a well-deserved vacation, we’ll work with you to ensure that your treatment continues uninterrupted. 

Financial assistance programs

Information on financial assistance programs.

Your SareptAssist Case Manager can also provide information on financial support options you may qualify for, including the Co-Pay Assistance Program, Patient Assistance Program, and other support programs designed to assist with access to treatment.

EXONDYS 51 patient Graysen, age 2, standing and pointing to the sky

 

EXONDYS 51 patient Graysen, age 2, standing and pointing to the sky

Meet Holly, Zyler, and Ashley.

Holly was devastated by her son Zyler's Duchenne diagnosis at age 3. Learn how Ashley, a SareptAssist Case Manager, provided the information Holly needed to get Zyler started on EXONDYS 51.

Watch Their Story
Logo for SareptAssist, the patient support program for EXONDYS 51 patients
Logo for SareptAssist, the patient support program for EXONDYS 51 patients

Questions about SareptAssist?

We are here to help.

 

Just give us a call at 1-888-SAREPTA (888-727-3782). Case Managers are available Monday – Friday 8:30am – 6:30pm ET.

Spanish-speaking Case Managers and interpreters for other languages are available. SareptAssist is a resource available only to those who have been prescribed EXONDYS 51. SareptAssist is only available in the U.S.

“My Case Manager, Ashley, really went above and beyond when I didn’t know what to expect. She guided me through the steps, followed up on my questions about insurance reimbursement, and helped us through the process of getting Zyler started on therapy.”

–Holly, Zyler’s mom

SareptAssist Case Manager Ashley and Zylers mom Holly, standing side by side outside and smiling

Meet Holly, Zyler's mom

Meet Holly, Zyler's mom

Related FAQs

How can I connect with other families of children with Duchenne?

Several advocacy organizations offer Duchenne patients and families the opportunity to come together at events throughout the year. Find out more about Duchenne advocacy groups.

Will my insurance cover EXONDYS 51?

Once your child is prescribed EXONDYS 51, you may enroll in SareptAssist, our patient support program. Your Case Manager will start a benefits investigation on your current insurance plan and can help explain details about your coverage. How SareptAssist can help.

See All FAQs

WHAT IS EXONDYS 51® (eteplirsen)?

EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51.

EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit that has not been proven. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, hives, fever, flushing, cough, difficulty breathing, wheezing, and low blood pressure have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Side effects that happened at least 25% more often in 8 patients treated with EXONDYS 51 by intravenous infusion than in 4 patients treated with an inactive intravenous infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

In patients who received EXONDYS 51 for up to 4 years in clinical studies, the following side effects were reported in at least 10% of patients and occurred more often than at the same dose of EXONDYS 51: vomiting, bruising, scratches, joint pain, rash, IV site pain, and infections of the upper airways.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

READ MORE

WHAT IS EXONDYS 51® (eteplirsen)?

EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51.

EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit that has not been proven. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, hives, fever, flushing, cough, difficulty breathing, wheezing, and low blood pressure have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Side effects that happened at least 25% more often in 8 patients treated with EXONDYS 51 by intravenous infusion than in 4 patients treated with an inactive intravenous infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

In patients who received EXONDYS 51 for up to 4 years in clinical studies, the following side effects were reported in at least 10% of patients and occurred more often than at the same dose of EXONDYS 51: vomiting, bruising, scratches, joint pain, rash, IV site pain, and infections of the upper airways.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).